Programs established by FDA to expedite patient access to medications

American Journal of Health-System Pharmacy

Volumn 60, Issue 4, 2003, Pages 339-345

  Motl, Susannah ^a   Miller, Sarah J ^c   Burns, Patrick ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; BUSULFAN; HYDROXYUREA; IMATINIB; RECOMBINANT ALPHA INTERFERON; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

BONE MARROW APLASIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CYTOPENIA; DRUG APPROVAL; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HEALTH CARE; HEALTH CARE ACCESS; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; LIVER TOXICITY; MUCOSA INFLAMMATION; NAUSEA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; ARTICLE; DRUG CONTROL; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SURVEILLANCE PROGRAM; ECONOMICS; HEALTH CARE DELIVERY; ORGANIZATION AND MANAGEMENT; PRESCRIPTION; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG INDUSTRY; HEALTH SERVICES ACCESSIBILITY; HUMANS; ORPHAN DRUG PRODUCTION; PIPERAZINES; PRESCRIPTIONS, DRUG; PYRIMIDINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0038283055     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.4.339     Document Type: Review

References (44)

1. Tufts Center for the Study of Drug Development. Outlook 2002. www.tufts.edu/med/csdd/images/otlk2002.pdf (accessed 2002 May 31.
2. FDA drug approval time edges up to 18.5 months in 2001. FDC Rep. 2002; 64(1):12-3.
3. New molecular entities approved in 2001. FDC Rep. 2002; 64(1):14-5.
4. Biologics approved in 2001. FDC Rep. 2001; 64(2):14.
5. Food and Drug Administration. Guidance for industry: fast track drug development programs - designation, development, and application review. www.fda. gov/cber/gdlns/fsttrk.pdf (accessed 2002 May 6).
6. Coccheto DM, The Food and Drug Administration's fast track designation: observations from the initial two years of this designation. Drug Inf J. 2000; 34:753-60.
7. Food and Drug Administration. CDER response to request for "fast-track" designation. www.fda.gov/cder/rdmt/internetftstats.htm (accessed 2002 Apr 23).
8. Center for Drug Education and Research. Approval package: Gleevec (imatinib mesylate) capsules. www.fda.gov/cder/foi/nda/2001/21335_Gleevec:htm (accessed 2002 Jun 5).
9. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645-52.
10. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood. 2002; 99:3530-9.
11. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood. 2002; 99:1928-37.
12. Druker B. STI571 (Gleevec/Glivec) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study (IRIS Study). Proc Am Soc Clin Oncol. 2002; 22(pt. 1):1a. Abstract.
13. New drug, antibiotic, and biological drug product regulations; accelerated approval - proposed rule. Fed Regist. 1992; 57:13234-42.
14. New drug, antibiotic, and biological drug product regulations; accelerated approval - final rule. Fed Regist. 1992; 57:58942-60.
15. 21 C.F.R. 314.510.
16. Faderl S, Talpaz M, Estrov Z et al. Mechanisms of disease: the biology of chronic myeloid leukemia. New Engl J Med. 1999; 341:164-72.
17. Sawyers CL. Medical progress: chronic myeloid leukemia. N Engl J Med. 1999; 340:1330-40.
18. Center for Drug Evaluation and Research. Manual of policies and procedures. Priority review policy. Chap. 6020.3. Rockville, MD: Food and Drug Administration; 1996.
19. Food and Drug Administration. The Orphan Drug Act (as amended). www. fda.gov/orphan/oda.htm (accessed 2002 May 6).
20. Haffner ME. Orphan drug product regulation - United States. Int J Clin Pharmacol Ther. 2002; 40:84-8.
21. Jemal A, Thomas A, Murray T et al. Cancer statistics 2002. CA Cancer J Clin. 2002; 52:23-47.
22. Gleevec (imatinib mesylate) package insert. East Hanover, NJ: Novartis Pharmaceutical Corp.; 2001.
23. Van Oossterom AT, Judson I, Verweji J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a Phase I study. Lancet. 2001; 358:1421-3.
24. Kawaguchi Y, Jinnai I, Nagai K et al. Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells. Leukemia. 2001; 15:590-4.
25. Frasca F, Vigneri P, Vella V et al. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor. Oncogene. 2001; 20:384556.
26. Kilic T, Alberta JA, Zdunek PR et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000; 60:5143-50.
27. Krystal GW, Honsawek S, Litz J et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000; 6:3319-26.
28. Kantarjian HM, O'Brien S, Anderlini P et al. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood. 1996; 87:3069-81.
29. Kantarjian HM, Talpaz M, Kontoyiannis D et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunomycin, high dose cytarabine and granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 1992; 10:398-405.
30. Kantarjian HM, Keating MJ, Talpaz M et al. Chronic myelogenous leukemia in blast crisis. Am J Med. 1987; 83:445-54.
31. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344:1038-42.
32. Hofmann EK, de Vos S, Elashoff D et al. Relation between resistance of Philadelphia-chromosome positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet. 2002; 359:481-6.
33. Von Bubnoff N, Schneller F, Peschel C et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome -positive leukemia in STI571: a prospective study. Lancet. 2002; 359:487-91.
34. Sawyers CL. Cancer treatment in the STI571 era: what will change? J Clin Oncol. 2001; 19(18 suppl):13S-6S.
35. Weisberg E, Griffin JD. Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist Updates. 2001; 4:22-8.
36. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med. 2002; 346:683-93.
37. Firm D, Timmins N. Experts to block the use of leukaemia treatment. http://main.pslgroup.com (accessed 2002 May 16).
38. Food and Drug Administration. Overview and risk-management issues for Lotronex tablets. www.fda.gov/ohrms/dockets/ac/00/backgrd/3627b2bb.pdf (accessed 2002 Jun 2).
39. Center for Drug Evaluation and Research. 1st Medication guide; synthetic thyroid hormone approval. News Along Pike [serial onlinel. 2000; 6(8):10. www.fda.gov/cder/pike/aug2000.pdf (accessed 2002 Jun 2).
40. Center for Drug Evaluation and Research. Questions and answers - Lotronex tablets. www.fda.gov/cder/drug/infopage/lotronex/lotronex-qa/htm (accessed 2002 May 20).
41. Lasser KE, Allen PD, Woolhandler SJ et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002; 287:2215-20.
42. Public Citizen's Health Research Group. Safety of new drugs cannot be known for many years. www.citizen.org/pressroom/release.cfm?ID=1097 (accessed 2002 Jun 5).
43. Sasich LD, Lurie P, Wolfe SM. The drug industry's performance in finishing postmarketing research (Phase IV) studies: a public citizen's health research group project. www.citizen.org/publications/release.cfm?ID=6721 (accessed 2002 Jun 5).
44. Food and Drug Administration. CDER 2000 report to the nation: improving public health through human drugs. www.fda.gov/cder/reports/RTN2000/RTN2000.pdf (accessed 2002 Jun 2).